Search results
This guideline applies to the management of indirect hyperbilirubinemia in neonates < 8 days of life and ≥ 35 weeks gestation. This guideline does not include the management of neonatal direct hyperbilirubinemia or hyperbilirubinemia in patients > 8 days of age.
Neonatal indirect hyperbilirubinemia (IHB) is caused by an imbalance in bilirubin production and elimination. Approximately 60% of term and 80% of preterm infants develop jaundice in the first week of age.
1 lis 2020 · Neonatal indirect hyperbilirubinemia (IHB) is caused by an imbalance in bilirubin production and elimination. Approximately 60% of term and 80% of preterm infants develop jaundice in the first week of age.
Almost all hyperbilirubinemia in the immediate neonatal period is unconjugated, which is termed indirect bilirubin, based on older laboratory measurement methods; conjugated bilirubin is termed direct bilirubin.
Neonatal hyperbilirubinemia is a common clinical problem encountered during the neonatal period, especially in the first week of life (2, 3). Nearly 8% to 11% of neonates develop hyperbilirubinemia.
5 sie 2022 · Infants 7 days or older with a persistently elevated TSB within 2 mg/dL of the phototherapy threshold may have prolonged indirect hyperbilirubinemia, which can be confirmed by measuring serum direct-reacting or conjugated bilirubin (ie, a fractionated bilirubin measure) in addition to total bilirubin.
1 sty 2024 · Understanding the evaluation and treatment of severe neonatal indirect hyperbilirubinemia is simplified by understanding the fundamental steps in heme metabolism and bilirubin conjugation and excretion (Fig. 42.1). These crucial steps include (1) red blood cell (RBC) lysis or death, (2) the conversion of heme into biliverdin by heme oxygenase ...
